Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia

Atherosclerosis

Volumn 124, Issue SUPPL., 1996, Pages

  Knipscheer, Haye C ^a   De Valois, J Claire ^a   Van Den Ende, Bram ^a,b   Ten Cate, Jan Wouter ^a   Kastelein, John J P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Ciprofibrate; Fibrinogen; Gemfibrozil; Hyperlipidaemia; Lipoproteins; Safety; Tolerability

Indexed keywords

CIPROFIBRATE; FIBRINOGEN; GEMFIBROZIL; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029782151     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05860-1     Document Type: Conference Paper

References (30)

1. Hunninghake DB, Peters JR. Effect of fibric acid derivatives on blood lipid and lipoprotein levels. Am J Med 1987;83:44.
2. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37.
3. Knipscheer HC, Nurmohamed MT, Van den Ende A, Plaat B, Pruijs HJW, Mulder WJ, Kastelein JJP. Gemfibrozil treatment of the high triglyceride-low HDL cholesterol trait in men with established atherosclerosis. J Intern Med 1994;236:377.
4. Shepherd J. Mechanism of action of fibrates. Postgrad Med J 1993;69(Suppl 1):S34.
5. Chakrabarti R, Fearnley GR, Evans JF. Effects of clofibrate on fibrinolysis, platelet stickiness, plasmafibrinogen, and serum-cholesterol. Lancet 1968;ii:1007.
6. Calvert GD, Blight L, Franklin J, Oliver J, Wise P, Gallus AS. The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus. Eur J Clin Pharmacol 1980;17:355.
7. Almer LO, Kjellström T. The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. Atherosclerosis 1986;61:81.
8. Leschke M, Höffken H, Schmidtsdorff A, Blanke H, Egbring R, Joseph K, Strauer BE. Einfluss von Fenofibrat auf Fibringenkonzentration und Blutfluiditat. Dtsch Med Wochenschr 1989;114:939.
9. 1+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemostas 1992;67:505.
10. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen levels in patients with primary hypercholesterolemia. Thromb Haemostas 1993;70:241.
11. Illingworth DR, Olsen GD, Cook SF, Sexton CJ, Wendell HA, Connor WE. Ciprofibrate in the therapy of type II hypercholesterolemia, a double-blind trial. Atherosclerosis 1982;44:211.
12. Rouffy J, Chanu B, Djian F, Goy Loeper J. Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apolipoprotein A and B. Atherosclerosis 1985;54:273.
13. Olsson AG, Orö L. Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipidemia. Atherosclerosis 1982;42:229.
14. Bruckert E, Gheron G, Dairou F. Comparisons of the efficacy and tolerance of ciprofibrate and gemfibrozil in the treatment of type IIa and IIb hyperlipidemias. Synth Med 1988;429:14.
15. Cattin L, Da Col PG, Feruglio FS, Finazzo L, Rimondo S, Descovich GC, Manzato E, Zambon S, Crepaldi G, Siepi D, Mannarino E, Ventura A. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study. Clin Ther 1990;12:482.
16. Todd PA, Ward A. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1988;36:314.
17. Simpson IA, Lorimer AR, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolemia. Thromb Haemostas 1985;54:442.
18. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237.
19. Molinaari E, Pichler P, Krempler F, Kostner G. A rapid screening method for pathological lipoprotein (a) concentrations by counterimmunoelectrophoresis. Clin Chem 1983;128:373.
20. Kupke IR, Worz-Zeugner S. Sequential microultracentrifugation of lipoproteins in 100 μl of serum. J Lipid Res 1986;27:988.
21. Friedewald WT, Levy RI, Fredickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1972;18:499.
22. Clauss A. Gerinnungsphysiologische Schnellmethode zur bestimmung de Fibrinogens. Acta Haematol 1957; 17:237.
23. Sackett DL, Haynes RB, Tugwell P. In: Sackett DL, Haynes B, Guyatt GH and Tugwell P. (eds.). Clinical Epidemiology: Basic Science for Clinical Medicine, 2nd Edn. Boston, Toronto, Canada: Little, Brown and Company, 1991.
24. Farnier M. Sanofi Winthrop.
25. O'Brien J, Etherington MD, Shuttleworth R, Adams C, Middleton JE. A pilot study of effect of gemfibrozil on some haematological parameters. Thromb Res 1982;26:275.
26. Laustiola K, Lassila R, Koskinen P, Pellinen T, Maninninen V. Gemfibrozil decreases platelet reactivity in patients with hyperchlosterolemia during physical stress. Clin Pharmacol Ther 1988;43:302.
27. Niort G, Bulgarelli A. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988;71:113.
28. Stringer MD, Steadman CA, Kakkar VV. Gemfibrozil in hyperlipidemic patients with peripheral arterial disease: some undiscovered actions. Curr Med Res Opin 1990;12:207.
29. Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemostas 1990;63:174.
30. Ernst E. Plasma fibrinogen - an independent cardiovascular risk factor. J Intern Med 1990;227:365.